Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Huizing

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1995
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesA Sparreboom, M T Huizing, J J Boesen, et al.
British Journal of Cancer|September 25, 1999
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patientsO van Tellingen, M T Huizing, V R Panday, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimenV R Panday, L J van Warmerdam, M T Huizing, et al.
Facts, Views & Vision in Obgyn|March 16, 2016
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesK Papadmitriou, X B Trinh, S Altintas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trialM T Huizing, J B Vermorken, H Rosing, et al.
Seminars in Oncology|October 1, 1994
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol)J H Beijnen, M T Huizing, W W ten Bokkel Huinink, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 1996
Isolation, purification and biological activity of major docetaxel metabolites from human fecesA Sparreboom, O Van Tellingen, E J Scherrenburg, et al.
Journal of Cancer Research and Clinical Oncology|October 29, 1999
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxelV R Nannan Panday, L J van Warmerdam, M T Huizing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2006
Small-cell carcinoma of the penile urethra: a case report and a short review of the literatureS Altintas, N Blockx, M T Huizing, et al.
Seminars in Oncology|August 1, 1997
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic functionV R Panday, M T Huizing, P H Willemse, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|January 1, 1995
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesA Sparreboom, M T Huizing, J J Boesen, et al.
British Journal of Cancer|September 25, 1999
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patientsO van Tellingen, M T Huizing, V R Panday, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimenV R Panday, L J van Warmerdam, M T Huizing, et al.
Facts, Views & Vision in Obgyn|March 16, 2016
The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesK Papadmitriou, X B Trinh, S Altintas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trialM T Huizing, J B Vermorken, H Rosing, et al.
Seminars in Oncology|October 1, 1994
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol)J H Beijnen, M T Huizing, W W ten Bokkel Huinink, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 1996
Isolation, purification and biological activity of major docetaxel metabolites from human fecesA Sparreboom, O Van Tellingen, E J Scherrenburg, et al.
Journal of Cancer Research and Clinical Oncology|October 29, 1999
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxelV R Nannan Panday, L J van Warmerdam, M T Huizing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2006
Small-cell carcinoma of the penile urethra: a case report and a short review of the literatureS Altintas, N Blockx, M T Huizing, et al.
Seminars in Oncology|August 1, 1997
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic functionV R Panday, M T Huizing, P H Willemse, et al.
Pageof 4